Biogen

Yahoo Finance • yesterday

Why Biogen Stock Was a Winner on Wednesday

Key Points The company continues to pivot away from its traditional strength in multiple sclerosis treatments. Its recent acquisition of Apellis Pharmaceuticals should wrap up soon, and it'll have quite an impact.10 stocks we like better... Full story

Yahoo Finance • 2 days ago

Stocks Pressured as Soaring Crude Prices Raise Inflation Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.19%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.57%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.20%.  June E-mini S&P futures (ESM26) are down -0.15%, and June E-mini Nasd... Full story

Yahoo Finance • 2 days ago

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

DelveInsight Business Research LLP The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La Roche/Ioni... Full story

Yahoo Finance • 2 days ago

Biogen Inc. Q1 2026 Earnings Call Summary

Biogen Inc. Q1 2026 Earnings Call Summary - Moby Strategic Transformation and Performance Drivers Management characterizes the current period as a pivot from four years of declining revenue to a growth phase driven by strategic reinvestm... Full story

Yahoo Finance • 2 days ago

Biogen (BIIB) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATE Wednesday, April 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Christopher ViehbacherHead of Development — Priya SinghalPresident, North America — Alisha AlaimoChief Financial... Full story

Yahoo Finance • 2 days ago

US Stock Market Today S&P 500 Futures Flat As Traders Await Fed Decision

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The Morning Bull - US Market Morning Update Wednesday, Apr, 29 202... Full story

Yahoo Finance • 4 days ago

Organon Stock Soars. It’s Riding the Pharma M&A Wave as Sun Seals Takeover.

India’s Sun Pharmaceutical Industries agrees to buy the women’s health company for $14 a share in an all-cash deal. Continue Reading... Full story

Yahoo Finance • 5 days ago

Earnings week ahead: MSFT, AAPL, GOOG, AMZN, META, XOM, CVX, KO, V, SBUX, F, GM, and more

[Magnifying Glass On Top Of Bar Chart Showing Decling Performance] DNY59/iStock via Getty Images As earnings season hits its peak, the week ahead stands out as one of the most consequential reporting stretches of the year. Five members o... Full story

Yahoo Finance • 6 days ago

3 Profitable Stocks We Steer Clear Of

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. Profits are valuable, but they’re not ev... Full story

Yahoo Finance • 7 days ago

Oncology Clinical Trials Research Report 2026: $20+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology clinical trials market has seen substantial growth, transitioning from $14.9... Full story

Yahoo Finance • 8 days ago

Jim Cramer Says “I Got to Reopen the File on Biogen”

Biogen Inc. (NASDAQ:BIIB) was among Jim Cramer’s stock calls on Mad Money recently. Toward the end of the lightning round, a caller asked what Cramer thinks of the stock, and he commented: Well, I read the upgrade today by Wells Fargo, an... Full story

Yahoo Finance • 9 days ago

UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Quick Read Biogen (BIIB) stock got an upgrade to Buy from UBS with a $225 price target, citing upcoming BIIB080 tau and litifilimab Phase 3 data as major catalysts over the next 12-15 months. Biogen trades at a 13x forward P/E—a notable d... Full story

Yahoo Finance • 9 days ago

Airbnb upgraded, Zscaler downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Airbnb (ABNB) to... Full story

Yahoo Finance • 9 days ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More

Quick Read The constant changing of the status regarding Iran and the Middle East has kept investors on edge, unsure which direction to proceed. First-quarter earnings continue to pour in, with many of the top companies posting solid resu... Full story

Yahoo Finance • 10 days ago

Biogen (BIIB) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATE Oct. 30, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Christopher Turner Chief Financial Officer — Ranjith Roy Senior Vice President and Corporate Controller — Dave Russell Vice P... Full story

Yahoo Finance • 10 days ago

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% gain. This was partly due to its solid quarterly results, and the performance may ha... Full story

Yahoo Finance • 10 days ago

FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment

[Roche] hapabapa * Roche (RHHBY [https://seekingalpha.com/symbol/RHHBY]) Tuesday said that the US Food and Drug Administration has accepted its supplemental Biologics License Application for Gazyva/Gazyvaro for the treatment of systemic... Full story

Yahoo Finance • 11 days ago

Biogen to buy China rights to immune disease drug for up to $850M

[Gratitude Concept With Heart Symbol] Eoneren Biogen (BIIB [https://seekingalpha.com/symbol/BIIB]) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed... Full story

Yahoo Finance • 11 days ago

Stocks making the biggest moves midday: Stanley Black & Decker, American Airlines, Dow, Marvell Technology & more

Check out the companies making the biggest moves in midday trading: Stanley Black & Decker — The power toolmaker jumped more than 4% after it said recent changes to Section 232 tariffs aren't supposed to have a material impact on its full-... Full story

Yahoo Finance • 11 days ago

Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act?

Quick Read Biogen (BIIB) stock received an upgrade from Wells Fargo to Overweight with a $250 price target from $200, driven by confidence in late-stage immunology and kidney pipeline programs as medium-term growth drivers beyond the comp... Full story